SLC5A2 and type 2 diabetes mellitus: Second, we aimed to compare the hypoglycemic effects of four SGLT2 inhibitors (dapagliflozin 5 mg and 10 mg, canagliflozin 100 mg and 300 mg, empagliflozin 10 mg and 25 mg, and ipragliflozin 50mg and 100 mg), simulate the 24-h UGE of these inhibitors in patients with T2DM and renal insufficiency, and investigate optimal dosage regimen for the SGLT2 inhibitor in these patients.